Fundz

Qlaris Bio reported raising $24 Million in an initial SEC Form D filing, from an offering of $24 Million

PRIVATEApr 22, 2024

Amount Raised

$24 Million

$24 Million sold, per SEC Form D (first sale Apr 11, 2024)

Round Type

Venture

DedhamBiotechnology

Quick answer

Qlaris Bio raised $24 Million in a funding round, dated April 11, 2024. Qlaris Bio is based in Dedham, Massachusetts, United States.

How much did Qlaris Bio raise?
Qlaris Bio raised $24 Million in a funding round on April 11, 2024.
What does Qlaris Bio do?
Qlaris is advancing QLS-111, a novel topical ocular therapy designed to lower intraocular pressure through a unique mechanism of action.
Where is Qlaris Bio based and how big is it?
Qlaris Bio is based in Dedham, Massachusetts, United States. Fundz records about 10 employees.
Who are the decision-makers at Qlaris Bio?
Fundz holds 1 contact at Qlaris Bio, including the Executive Officer, Director. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Qlaris Bio that raised within 45 days of this round, from Fundz verified event records.

  • Bionano Genomics raised $20M on May 24, 2024.
  • Bicycle Therapeutics raised $555M (Post-IPO Equity) on May 23, 2024.
  • Grey Wolf Therapeutics raised $50M (Series B) on May 23, 2024.
  • Radar Therapeutics raised $13M (Seed) on May 23, 2024.
  • Turn Therapeutics Inc. raised an undisclosed amount on May 23, 2024.
  • Kolon TissueGene, Inc. raised $35M on May 23, 2024.

Who to call at Qlaris Bio, and when

A new round usually means Qlaris Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Qlaris Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Qlaris Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Qlaris Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Qlaris Bio

Location

770 Legacy Place

Dedham, Massachusetts, United States

About

Qlaris is advancing QLS-111, a novel topical ocular therapy designed to lower intraocular pressure through a unique mechanism of action. Unlike current treatments, QLS-111 selectively targets episcleral venous pressure (EVP) and enhances outflow distal to the trabecular meshwork. This innovative approach may offer improved treatment options for conditions in which EVP is limited or pathological, including Normal Tension Glaucoma, Primary Open Angle Glaucoma, and glaucoma associated with Sturge-Weber Syndrome. QLS-111 may also be used alongside Minimally-Invasive Glaucoma Surgery (MIGS) devices to further optimize outcomes.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Qlaris Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsThurein H., Executive Officer, Director hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Qlaris Bio's next move

See what Strategic adds

Qlaris Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.